Abstract:While synergistic drug combinations are more effective at fighting tumors with complex pathophysiology, preference compensating mechanisms, and drug resistance, the identification of novel synergistic drug combinations, especially complex higher-order combinations, remains challenging due to the size of combination space. Even though certain computational methods have been used to identify synergistic drug combinations in lieu of traditional in vitro and in vivo screening tests, the majority of previously published work has focused on predicting synergistic drug pairs for specific types of cancer and paid little attention to the sophisticated high-order combinations. The main objective of this study is to develop a deep learning-based approach that integrated multi-omics data to predict novel synergistic multi-drug combinations (DeepMDS) in a given cell line. To develop this approach, we firstly created a dataset comprising of gene expression profiles of cancer cell lines, target information of anti-cancer drugs, and drug response against a large variety of cancer cell lines. Based on the principle of a fully connected feed forward Deep Neural Network, the proposed model was constructed using this dataset, which achieved a high performance with a Mean Square Error (MSE) of 2.50 and a Root Mean Squared Error (RMSE) of 1.58 in the regression task, and gave the best classification accuracy of 0.94, an area under the Receiver Operating Characteristic curve (AUC) of 0.97, a sensitivity of 0.95, and a specificity of 0.93. Furthermore, we utilized three breast cancer cell subtypes (MCF-7, MDA-MD-468 and MDA-MB-231) and one lung cancer cell line A549 to validate the predicted results of our model, showing that the predicted top-ranked multi-drug combinations had superior anti-cancer effects to other combinations, particularly those that were widely used in clinical treatment. Our model has the potential to increase the practicality of expanding the drug combinational space and to leverage its capacity to prioritize the most effective multi-drug combinational therapy for precision oncology applications.

DTSyn: a Dual-Transformer-based Neural Network to Predict Synergistic Drug Combinations

DualSyn: A Dual-Level Feature Interaction Method to Predict Synergistic Drug Combinations

MDNNSyn: A Multi-Modal Deep Learning Framework for Drug Synergy Prediction

A Deep Neural Network for Predicting Synergistic Drug Combinations on Cancer

DTF: Deep Tensor Factorization for predicting anticancer drug synergy

AttenSyn: An Attention-Based Deep Graph Neural Network for Anticancer Synergistic Drug Combination Prediction

Synergistic Drug Combination Prediction by Integrating Multi-omics Data in Deep Learning Models

MMSyn: A New Multimodal Deep Learning Framework for Enhanced Prediction of Synergistic Drug Combinations

DFFNDDS: Prediction of Synergistic Drug Combinations with Dual Feature Fusion Networks

An In Silico Method for Predicting Drug Synergy Based on Multitask Learning

DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations

Unlocking the therapeutic potential of drug combinations through synergy prediction using graph transformer networks

SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction

Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning

HetBiSyn: Predicting Anticancer Synergistic Drug Combinations Featuring Bi-perspective Drug Embedding with Heterogeneous Data.

MFSynDCP: multi-source feature collaborative interactive learning for drug combination synergy prediction

Trustworthy Deep Neural Network for Inferring Anticancer Synergistic Combinations

DSA-DeepFM: A Dual-Stage Attention-Enhanced DeepFM Model for Predicting Anticancer Synergistic Drug Combinations

Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies

Ensemble Prediction of Synergistic Drug Combinations Incorporating Biological, Chemical, Pharmacological, and Network Knowledge